8 November 2022FeaturesMuireann Bolger

Sea change: a Q&A with Kathi Vidal

You have always been a proponent of diversity and inclusion. What drove you to make that an area of focus?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Careers

Former USPTO acting director takes the helm at C4IP

17 August 2026 The IP advocacy group has turned to former USPTO acting director Coke Morgan Stewart as it enters what it calls a “new chapter”.

Biotech

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.

Pharma

Novartis scores UK win in high-stakes Entresto fight

14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.

More features

Former USPTO acting director takes the helm at C4IP

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

The UPC plugs another gap in its procedural rulebook

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

Exclusive: ‘Cultural differences are an asset’ at the UPC

Sea change: a Q&A with Kathi Vidal

More on this story

Editor's picks

Editor's picks

More features